Over the summer, we saw the first half of the circus that healthcare reform has become: Tea Partiers and Town Hallers screaming at members of Congress not to kill grandma or socialize their Medicare. Now we’re in the middle of the second act: trying to move the legislation through the Senate. With all of the horse trading, showboating, and lack of good-faith negotiations on the part of some individuals, this whole issue has become more complicated than it deserves to be.
For example, a plan to offer a Medicare buy-in for seniors 55 and older was shot down after lacking the votes. At the same time, the chance for a public option has gone down the drain, thanks to a handful of moderates. Has anyone ever considered that a public option (not to mention a full-blown single-payer system) would make any discussion of Medicare and Medicaid moot? If people were given the choice to buy an insurance plan offered by the government, we could eliminate those two programs altogether. Low-income people would be subsidized under the government plan until they are able to gain insurance through their employer (assuming that they would want to switch plans), and elderly people could enroll in a subsidized plan when they retire; there would be no onerous eligibility requirements and everyone would be allowed to purchase coverage under it.
Another frustrating impasse: Senator Byron Dorgan’s (D-N.D.) amendment to allow Americans to buy imported medications at lower prices than their American-made counterparts. Obviously, there are concerns about the safety of drugs that are not produced in this country, but given the widespread salmonella outbreak in peanut products earlier this year, one has to wonder whether the FDA could effectively protect us even if it were given the resources to. Yet, the amendment is unlikely to pass because of lobbying by the pharmaceutical industry. They agreed to cut the cost of prescription medications for seniors in order to save $80 billion over ten years, but heaven forbid they be expected to lower their prices for everyone—to the tune of several hundred dollars for some drugs—when competition is introduced into the market.
I am sympathetic to drug manufacturers to a certain point. That point is when the focus turns from researching new cures to making obscene profits off of Americans’ health. In 2002, the top ten drug makers in the U.S. spent 14 percent of their revenue on research and development, while spending 31 percent on marketing. What does marketing entail? Trying to persuade doctors and patients to choose one drug over other similar medications on the market (“me-too” drugs), for starters. And, of course, billions are spent lobbying members of Congress to ease the burdens of regulation and competition.
The underlying problem with drug and insurance companies is that these enterprises have to reconcile the business necessity of making profit with the social obligation to keep Americans healthy. But really, is there any doubt which side of the operation takes precedence? President Obama has had the same problem with banks, who have kept a tight lid on credit in order to maintain high profit margins. He is trying to persuade bankers to moderate their extravagant pay and remind them of an obligation to help the taxpayers who bailed them out. Perhaps the president sees corporate America as a community in need of an organizer, but really it is a collection of bullies in need of discipline.
America is the only industrialized country that does not limit drug prices in some way. I doubt that there is political will to enact price controls, which is a shame, since I would prefer to go many steps further and nationalize the drug and insurance industries. People who scream about “government takeovers” say that this is bad for business, but doesn’t that bring up the possibility that such a move is good for consumers? Just consider, the salary of Arden Bement, Jr., the director of the National Science Fondation, was $172,000 in 2008. The salary of David Brennan, AstraZeneca CEO, was $4.3 million in 2007. Does Brennan, who started his career as a sales representative—i.e. marketer—for a drug company, add any more value to the corpus of scientific knowledge than Dr. Bement—a professor of nuclear engineering? Probably not, but he sure knows how to turn a profit for his company.
Obviously, there is a place for the profit motive in stimulating innovation. But I wish that Congress would take a candid look at what measures need to be implemented that would truly restrain the healthcare industry from denying affordable treatment to Americans without compromising their ability to remain competitive in the field of research.






